The US drug regulator conducted the current Good Manufacturing Practices (cGMP) inspection from August 17 to August 25 and issued the observations in a Form 483, Cipla said in an exchange filing on Tuesday.
A Form 483 flags conditions or practices that USFDA inspectors believe may violate regulatory requirements. It isn’t, by itself, a final regulatory action against the company or the plant.
Cipla did not disclose the nature or severity of the seven observations.
Cipla says it will address observations
The drugmaker said it would work with the USFDA to address the observations within the stipulated timeline.
The latest inspection was described by Cipla as a follow-up cGMP inspection. The company had previously made regulatory disclosures concerning the Pithampur facility in February, August and November 2023.
The next key development will be Cipla’s response to the observations and the USFDA’s assessment of the corrective measures proposed by the company.
The number of observations alone doesn’t establish their seriousness. Form 483 observations can cover a range of manufacturing and compliance issues, and their implications depend on what inspectors identified and how satisfactorily the company addresses them.
What is a USFDA Form 483?
The USFDA issues a Form 483 at the end of an inspection when its investigators observe conditions that, in their judgment, may constitute violations of US food and drug regulations.
Companies are generally expected to respond to the observations and explain the corrective actions they intend to take.
For Indian pharmaceutical companies selling medicines in the US, regulatory compliance at manufacturing plants is closely watched because unresolved issues can potentially affect approvals and supplies to the world’s largest pharmaceutical market.
The issuance of a Form 483, however, doesn’t constitute a final determination by the USFDA.
Cipla’s quarterly profit at ₹789 crore
The regulatory development comes after Cipla reported consolidated net profit of ₹789 crore for the quarter, while revenue from operations increased 2.3% year-on-year to ₹7,119 crore from ₹6,957.5 crore.
The company said revenue growth was driven by its India, Africa and emerging-markets businesses, partly offset by weakness in North America.
Operating performance was weaker. Earnings before interest, tax, depreciation and amortisation (EBITDA) fell 33% to ₹1,192 crore from ₹1,778.1 crore a year earlier, while the EBITDA margin narrowed to 16.7% from 25.6%.
Total tax expense stood at ₹295 crore, compared with ₹478 crore in the year-ago quarter.
Cipla shares closed 1.59% lower at ₹1,415 on Tuesday. The stock is down 5.9% so far in 2026 and about 11.2% over the past year.
